Privacy Reforms Could Speed Trial Enrollment, Stakeholders Tell Congress
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry says relaxation of HIPPA could take years off drug research and enable new clinical trial networks, but is less willing to de-privatize its own data.